Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Levy

Orthopaedic Surgery Boca Raton, FL Medical Doctor

NPI 1013980952 CMS profile 1301894

9960 Central Park Blvd N Ste 150A, Boca Raton, FL 33428

Open in the dashboard

General payments

$4,760,549

953 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$221,667

2 holdings reported · through program year 2025

Research they led as principal investigator

$436,370 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jonathan Levy of Boca Raton, FL is reported in the CMS Open Payments database as having received $4,760,549 across 953 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $436,370 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $221,667 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $952,771 113
2024 General $710,182 113
2023 General $736,739 185
2022 General $772,998 191
2021 General $508,534 140
2020 General $481,756 93
2019 General $597,569 118
2024 Ownership $110,833 1
2023 Ownership $110,833 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Levy
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Jonathan Levy were reported at $952,771. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Jonathan Levy Orthopaedic Surgery median Middle half National median
2019 $597,569 $644 $140–$2,844 $163
2020 $481,756 $312 $75–$1,860 $114
2021 $508,534 $520 $117–$2,495 $132
2022 $772,998 $598 $128–$2,731 $149
2023 $736,739 $461 $128–$2,264 $160
2024 $710,182 $497 $134–$2,475 $164
2025 $952,771 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Encore Medical, LP $4,475,871 732 payments
  2. Stryker Corporation $127,652 90 payments
  3. Globus Medical, Inc. $90,614 65 payments
  4. Exactech, Inc. $31,494 28 payments
  5. Insight Medical Systems, Inc. $26,327 16 payments
  6. Djo, LLC $5,021 3 payments
  7. Southern Edge Orthopaedics, Inc. $1,742 1 payment
  8. Medtronic, Inc. $1,048 6 payments
  9. Zimmer Biomet Holdings, Inc. $397 4 payments
  10. Catalyst OrthoScience $128 1 payment
  11. Other $256 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $2,818,377 46 payments
  2. Consulting Fee $1,734,774 541 payments
  3. Travel and Lodging $93,644 151 payments
  4. Acquisitions $75,000 1 payment
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,750 4 payments
  6. Food and Beverage $11,492 207 payments
  7. Honoraria $1,771 2 payments
  8. Education $1,742 1 payment
Products named General payments · program years 2019–2025
  1. DJO SURGICAL Joint Implants $2,629,733 267 payments
  2. DJO SURGICAL Joint Implants $1,593,912 219 payments
  3. DJO SURGICAL Joint Implants $1,141,428 15 payments
  4. DJO Surgical AltiVate Reverse Joint Implants $920,492 122 payments
  5. DJO Surgical AltiVate Reverse Joint Implants $433,970 57 payments
  6. DJO Surgical AltiVate Anatomic System Joint Implants $229,787 93 payments
  7. DJO SURGICAL Joint Implants $191,366 79 payments
  8. DJO Surgical AltiVate Anatomic System Joint Implants $83,924 75 payments
  9. DJO Surgical Match Point System $81,033 51 payments
  10. DJO SURGICAL Joint Implants $62,954 12 payments
  11. Other $537,236 287 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

63

Median for Orthopedic Surgery: 203

Drug cost

$235

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 63 $235

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$641,712

Of which drugs: $859

Medicare patients

1,212

Average age 76

Services billed

5,319

714 women, 498 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 43%
Osteoporosis 28%
Diabetes 26%
Depression 26%
Chronic kidney disease 22%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 245 1,160 $859

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

953 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record